Saturday, April 22, 2017 12:49:52 AM
Apr. 19, 2017 5:03 PM ET|5 comments| About: Progenics Pharmaceuticals Inc. (PGNX)
Emerging Equities
Emerging Equities
Special situations, long/short equity
(308 followers)
Summary
Progenics has seen some price fall despite good news from the Azedra trial.
This is simple market efficiency and should not worry investors.
Progenics is a buy at these prices.
https://seekingalpha.com/article/4063518-progenics-moves-ahead-towards-nda-filing-azedra
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM